以其Omnipod胰岛素供应系统著称的Insulet公司,在美国Mizuho证券公司领导下,机构投资激增。 Insulet Corp, known for its Omnipod insulin delivery system, saw a surge in institutional investments, led by Mizuho Securities USA.

Insulet Corp 生产 Omnipod 等胰岛素输送系统，第三季度的机构投资大幅增加。 Insulet Corp, which makes insulin delivery systems like the Omnipod, saw a big increase in institutional investments during the third quarter. 美国Mizuho证券有限公司率先将股份增加5 928.1%,现在拥有价值7 580万美元的股权。 Mizuho Securities USA LLC led the way by boosting its stake by 5,928.1%, now owning $75.8 million worth of shares. 其他投资者也增加了它们的持有量。 Other investors also increased their holdings. 该股票于星期五开放260.12美元,市场上限为182.5亿美元,从分析人员那里得到的评级大多是正面的。 The stock, which opened at $260.12 on Friday, has a market cap of $18.25 billion and has received mostly positive ratings from analysts.